月度归档： 2026 年 7 月

[Disclosure: AgFunderNews’ parent company AgFunder is an investor in Plantik Biosciences.] Can editing the so-called “da…

世界农化网中文网报道： 几十年来，种子包衣行业一直依赖合成石油基聚合物的可靠性能。这些物质发挥了至关重要的作用：它们将保护性的杀菌剂、杀虫剂和着色剂固定在种子表面，确保种子在高速播种机械中顺畅流动，并减少了有害粉尘向空气及农民劳作区域的释放。

The approach to sequencing genetic material has evolved over the decades. When next generation sequencing (NGS) arrived in the market at the beginning of this century, it replaced the slow and expensive Sanger sequencing, allowing several DNA fragments to be read simultaneously. Much of the world’s NGS has been performed by Illumina, which has historically produced about 90% of the world’s genomic data. Various sequencers have attempted to topple Illumina’s dominance, but Illumina continues to lead the genomic sequencing space. Now with the entry of Roche’s AXELIOS 1, could it break Illumina’s long-standing hold over the market? 

Why it matters: The ETH Zurich spinout is trying to replace the complex process used by current gene-edited cell therapies with an off-the-shelf injection that edits cells directly inside the body.

July 2026, London: Increased segmentation in Europe’s recycled low density polyethylene (rLDPE) market has prompte…

U.S. biotech company Phinomics has established its European hub at Bayer Co.Lab Berlin, bringing a research focus that could reshape how scientists understand tumor evolution and drug resistance. Rather than concentrating solely on artificial intelligence, the Stanford University spinout is betting on an overlooked biological driver of cancer: extrachromosomal circular DNA (eccDNA), small circular DNA molecules that exist outside chromosomes and may play a key role in tumor progression and treatment resistance.

The Israeli trustee tasked with selling the intellectual property assets of defunct cultivated meat startup Believer Mea…

Samsung Biologics of South Korea has offered shareholders CHF44.31 per share in cash, valuing PolyPeptide’s equity at approximately CHF1.46 billion.

In a  new study published in  Leukemia  titled, “ Spatial remodeling of bone marrow architecture defines tissue-state signatures of disease activity and therapeutic response in myelodysplastic neoplasm , “ researchers from Weill Cornell Medicine have developed a new AI-based method to assess patients with a form of blood cancer called myelodysplastic neoplasms (MDS). The approach compares the size and shape characteristics of hematopoietic cells in the patient’s bone marrow sample with those in healthy bone marrow to generate a score that reflects disease severity.